Search research articles
Contact Us
Filters
Showing results (41-50 of 79) with videos related to
Page
of 8
Sort By:
Advances in Therapy
|
April 21, 2015
Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
François Laliberté, Michel Cloutier, Concetta Crivera, et al.
Clinical Nephrology
|
December 13, 2017
Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function
Matthew R Weir, Lloyd Haskell, Jeffrey S Berger, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|
May 27, 2016
External Validation of the Hestia Criteria for Identifying Acute Pulmonary Embolism Patients at Low Risk of Early Mortality
Erin R Weeda, Christine G Kohn, W Frank Peacock, et al.
Current Medical Research and Opinion
|
September 29, 2018
Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients
Colleen A McHorney, Eric D Peterson, Veronica Ashton, et al.
Clinical Therapeutics
|
March 10, 2015
Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users
François Laliberté, Michel Cloutier, Concetta Crivera, et al.
Advances in Therapy
|
March 19, 2015
Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users
François Laliberté, Michel Cloutier, Concetta Crivera, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
January 31, 2019
Comparison of real-world outcomes in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin
Manasi Datar, Concetta Crivera, Heather Rozjabek, et al.
Pharmacotherapy
|
August 23, 2016
Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism
Erin R Weeda, Christine G Kohn, W Frank Peacock, et al.
Journal of Managed Care & Specialty Pharmacy
|
August 31, 2017
Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation
Colleen A McHorney, Veronica Ashton, François Laliberté, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
February 9, 2019
Duration of anticoagulant therapy and VTE recurrence in patients with cancer
Alok A Khorana, Keith R McCrae, Dejan Milentijevic, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 79) with videos related to
Sort By:
Page
of 8
Advances in Therapy
|
April 21, 2015
Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
François Laliberté, Michel Cloutier, Concetta Crivera, et al.
Clinical Nephrology
|
December 13, 2017
Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function
Matthew R Weir, Lloyd Haskell, Jeffrey S Berger, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|
May 27, 2016
External Validation of the Hestia Criteria for Identifying Acute Pulmonary Embolism Patients at Low Risk of Early Mortality
Erin R Weeda, Christine G Kohn, W Frank Peacock, et al.
Current Medical Research and Opinion
|
September 29, 2018
Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients
Colleen A McHorney, Eric D Peterson, Veronica Ashton, et al.
Clinical Therapeutics
|
March 10, 2015
Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users
François Laliberté, Michel Cloutier, Concetta Crivera, et al.
Advances in Therapy
|
March 19, 2015
Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users
François Laliberté, Michel Cloutier, Concetta Crivera, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
January 31, 2019
Comparison of real-world outcomes in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin
Manasi Datar, Concetta Crivera, Heather Rozjabek, et al.
Pharmacotherapy
|
August 23, 2016
Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism
Erin R Weeda, Christine G Kohn, W Frank Peacock, et al.
Journal of Managed Care & Specialty Pharmacy
|
August 31, 2017
Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation
Colleen A McHorney, Veronica Ashton, François Laliberté, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
February 9, 2019
Duration of anticoagulant therapy and VTE recurrence in patients with cancer
Alok A Khorana, Keith R McCrae, Dejan Milentijevic, et al.
Page
of 8